Calcium-channel blockers and the hepatorenal syndrome.
It is suggested that calcium-channel blockers may be the agents of choice for treating the renal dysfunction associated with the hepatorenal syndrome because these agents may be effective in reversing the episodic renal vasospasm which characterizes this disorder.
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000098:blood supply; D007674:Kidney Diseases / Q000188:drug therapy*; D014661:Vasoconstriction
D002121:Calcium Channel Blockers